Ipsen

News

Ipsen to buy rare disease firm Clementia for up to $1.31bn

France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.

News

Chinese patients to get new drugs before UK after Brexit - s...

US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview.

News

Ipsen warns over medicine supplies amid Brexit uncertainty

France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma industry and patients’ access to medicines.

News

Known as Cabometyx in the US, the drug is licensed by Ipsen from Exelixis

EU approves Ipsen's Cabometyx in second line liver cancer

The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar.

News

EU regulators back Ipsen cancer drug in new liver cancer use

Ipsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed it in a new indication of second line liver cancer – a use whe

News

Ipsen appoints new general manager for the UK & Ireland

The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali, who brings two decades of commercial experience and a bold vision for Ipsen’s globa

Ipsen to buy rare disease firm Clementia for up to $1.31bn

Chinese patients to get new drugs before UK after Brexit - s...

Ipsen warns over medicine supplies amid Brexit uncertainty

EU approves Ipsen's Cabometyx in second line liver cancer

EU regulators back Ipsen cancer drug in new liver cancer use

Ipsen appoints new general manager for the UK & Ireland

Novo Nordisk gets FDA okay for Wegovy pill

How to meet your physicians where they are online

Ipsen

Editor's Picks